Antimicrobial stewardship in patients with cancer

Pharmacotherapy

Volumn 32, Issue 8, 2012, Pages 722-734

  Tverdek, Frank P ^a   Rolston, Kenneth V ^b   Chemaly, Roy F ^a,c  

^a Department of Pharmacy Clinical Programs ^*  (United States)

^b Department of Infectious Diseases Infection Control and Employee Health   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Antibiotic; Antimicrobial; Audit; Cycling; Hematology; Oncology; Restriction; Stewardship

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; AZTREONAM; BIOLOGICAL MARKER; CEFAZOLIN; CEFEPIME; CEFTAZIDIME; CILASTATIN PLUS IMIPENEM; CIPROFLOXACIN; CLINDAMYCIN; IMIPENEM; LINEZOLID; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; PLACEBO; QUINOLINE DERIVED ANTIINFECTIVE AGENT; TOBRAMYCIN; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIMICROBIAL STEWARDSHIP; ANTIMICROBIAL THERAPY; BACTERIAL INFECTION; CANCER PATIENT; CLINICAL PRACTICE; CLOSTRIDIUM DIFFICILE INFECTION; DRUG CHOICE; DRUG CONTROL; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; DRUG USE; DRUG WITHDRAWAL; ELECTRONIC PRESCRIBING; FEBRILE NEUTROPENIA; HEALTH CARE; HUMAN; INFECTION CONTROL; INFECTION PREVENTION; KIDNEY FAILURE; MEDICAL AUDIT; MULTIPLE CYCLE TREATMENT; MYCOSIS; OUTPATIENT CARE; REVIEW; RISK BENEFIT ANALYSIS; SEIZURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ANTI-INFECTIVE AGENTS; DRUG RESISTANCE, MICROBIAL; HOSPITALS; HUMANS; INFECTION; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; TREATMENT OUTCOME;

EID: 84864574214     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1002/j.1875-9114.2012.01162.x     Document Type: Review

References (66)

1. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Infectious Diseases Society of A. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of america. Clin Infect Dis 2011;52(4):e56-93.
2. Dellit TH, Owens RC, McGowan JE Jr, et al. Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis 2007;44(2):159-77.
3. Zuckermann J, Moreira LB, Stoll P, Moreira LM, Kuchenbecker RS, Polanczyk CA. Compliance with a critical pathway for the management of febrile neutropenia and impact on clinical outcomes. Ann Hematol 2008;87(2):139-45.
4. Paskovaty A, Pflomm JM, Myke N, Seo SK. A multidisciplinary approach to antimicrobial stewardship: Evolution into the 21st century. Int J Antimicrob Agents 2005;25(1):1-10.
5. Safdar A, Bodey G., Armstrong D. Infections in Patients with Cancer: Overview. In: Safdar A, ed. Principles and practice of cancer infectious diseases. New York: Humana Press, 2011: 3-16.
6. Rolston KV. Challenges in the treatment of infections caused by gram-positive and gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis 2005;40(Suppl 4):S246 -52.
7. Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966;64(2):328-40.
8. Ohmagari N, Hanna H, Graviss L, et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer 2005;104(1):205-12.
9. Mihu CN, Rhomberg PR, Jones RN, Coyle E, Prince RA, Rolston KV. Escherichia coli resistance to quinolones at a comprehensive cancer center. Diagn Microbiol Infect Dis 2010;67 (3):266-9.
10. Rangaraj G, Granwehr BP, Jiang Y, Hachem R, Raad I. Perils of quinolone exposure in cancer patients. Cancer 2010;116 (4):967-73.
11. Cadena J, Taboada CA, Burgess DS, et al. Antibiotic cycling to decrease bacterial antibiotic resistance: A 5-year experience on a bone marrow transplant unit. Bone Marrow Transplant 2007;40(2):151-5.
12. Cheng VCC, To KKW, Li IWS, et al. Antimicrobial stewardship program directed at broad-spectrum intravenous antibiotics prescription in a tertiary hospital. Eur J Clin Microbiol Infect Dis 2009;28(12):1447-56.
13. Craig M, Cumpston AD, Hobbs GR, Devetten MP, Sarwari AR, Ericson SG. The clinical impact of antibacterial prophylaxis and cycling antibiotics for febrile neutropenia in a hematological malignancy and transplantation unit. Bone Marrow Transplant 2007;39(8):477-82.
14. Dominguez EA, Smith TL, Reed E, Sanders CC, Sanders WE Jr. A pilot study of antibiotic cycling in a hematology-oncology unit. Infect Control Hosp Epidemiol 2000;21(Suppl 1):S4-8.
15. Nucci M, Landau M, Silveira F, Spector N, Pulcheri W. Application of the IDSA guidelines for the use of antimicrobial agents in neutropenic patients: Impact on reducing the use of glycopeptides. Infect Control Hosp Epidemiol 2001;22(10):651-3.
16. Shaikh ZH, Osting CA, Hanna HA, Arbuckle RB, Tarr JJ, Raad II. Effectiveness of a multifaceted infection control policy in reducing vancomycin usage and vancomycin-resistant enterococci at a tertiary care cancer centre. J Hosp Infect 2002;51(1):52-8.
17. Yeo CL, Chan DS, Earnest A, et al. Prospective audit and feedback on antibiotic prescription in an adult hematologyoncology unit in Singapore. Eur J Clin Microbiol Infect Dis 2011;31(4):583-90.
18. Bradley SJ, Wilson AL, Allen MC, Sher HA, Goldstone AH, Scott GM. The control of hyperendemic glycopeptide-resistant Enterococcus spp. on a haematology unit by changing antibiotic usage. J Antimicrob Chemother 1999;43(2):261-6.
19. Mihu CN, Paskovaty A., Seo SK. Antimicrobial stewardship: Considerations for a cancer center. In: Safdar A, ed. Principles and practice of cancer infectious diseases 2011:491-8.
20. Rolston KV. The use of new and better antibiotics for bacterial infections in patients with leukemia. Clin Lymphoma Myeloma 2009;9(Suppl 3):S357-63.
21. Chopra T, Alangaden GJ, Chandrasekar P. Clostridium difficile infection in cancer patients and hematopoietic stem cell transplant recipients. Expert Rev Anti Infect Ther 2010;8 (10):1113-9.
22. Saito T, Yoshioka S, Iinuma Y, et al. Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology- oncology unit. Eur J Clin Microbiol Infect Dis 2007;27(3):209-16.
23. Worth LJ, Thursky KA, Seymour JF, Slavin MA. Vancomycinresistant Enterococcus faecium infection in patients with hematologic malignancy: Patients with acute myeloid leukemia are at high-risk. Eur J Haematol 2007;79(3):226-33.
24. Eagye KJ, Kuti JL, Nicolau DP. Risk factors and outcomes associated with isolation of meropenem high-level-resistant Pseudomonas aeruginosa. Infect Control Hosp Epidemiol 2009;30(8):746-52.
25. Obritsch MD, Fish DN, MacLaren R, Jung R. Nosocomial infections due to multidrug-resistant Pseudomonas aeruginosa: Epidemiology and treatment options. Pharmacotherapy 2005;25(10):1353-64.
26. DiazGranados CA, Jernigan JA. Impact of vancomycin resistance on mortality among patients with neutropenia and enterococcal bloodstream infection. J Infect Dis 2005;191(4):588-95.
27. McGowan JE Jr. Antimicrobial resistance in hospital organisms and its relation to antibiotic use. Rev Infect Dis 1983;5 (6):1033-48.
28. Shlaes DM, Gerding DN, John JF Jr, et al. Society for Healthcare Epidemiology of America and Infectious Diseases Society of America Joint Committee on the Prevention of Antimicrobial Resistance: Guidelines for the prevention of antimicrobial resistance in hospitals. Clin Infect Dis 1997;25(3):584-99.
29. Diazgranados CA. Prospective audit for antimicrobial stewardship in intensive care: Impact on resistance and clinical outcomes. Am J Infect Control [Internet]. 2011; Sept 20 [Cited 2012 May 4]; E4. Available from: Http://www.sciencedirect.com/ science/article/pii/S0196655311009722.
30. Kaki R, Elligsen M, Walker S, Simor A, Palmay L, Daneman N. Impact of antimicrobial stewardship in critical care: A systematic review. J Antimicrob Chemother 2011;66(6):1223-30.
31. Yong MK, Buising KL, Cheng AC, Thursky KA. Improved susceptibility of Gram-negative bacteria in an intensive care unit following implementation of a computerized antibiotic decision support system. J Antimicrob Chemother 2010;65 (5):1062-9.
32. Kern WV, Klose K, Jellen-Ritter AS, et al. Fluoroquinolone resistance of Escherichia coli at a cancer center: Epidemiologic evolution and effects of discontinuing prophylactic fluoroquinolone use in neutropenic patients with leukemia. Eur J Clin Microbiol Infect Dis 2005;24(2):111-8.
33. Ng ES, Liew Y, Earnest A, Koh LP, Lim SW, Hsu LY. Audit of fluoroquinolone prophylaxis against chemotherapy-induced febrile neutropenia in a hospital with highly prevalent fluoroquinolone resistance. Leuk Lymphoma 2011;52(1):131-3.
34. Klastersky J, Paesmans M, Rubenstein EB, et al. The Multinational Association for Supportive Care in Cancer risk index: A multinational scoring system for identifying low-risk febrile neutropenic cancer patients. J Clin Oncol 2000;18(16):3038-51.
35. Gafter-Gvili A, Paul M, Fraser A, Leibovici L. Effect of quinolone prophylaxis in afebrile neutropenic patients on microbial resistance: Systematic review and meta-analysis. J Antimicrob Chemother 2007;59(1):5-22.
36. Imran H, Tleyjeh IM, Arndt CA, et al. Fluoroquinolone prophylaxis in patients with neutropenia: A meta-analysis of randomized placebo-controlled trials. Eur J Clin Microbiol Infect Dis 2008;27(1):53-63.
37. Lingaratnam S, Thursky KA, Slavin MA. Fluoroquinolone prophylaxis: A word of caution. Leuk Lymphoma 2011;52(1):5-6.
38. Bow EJ, Rotstein C, Noskin GA, et al. A randomized, openlabel, multicenter comparative study of the efficacy and safety of piperacillin- tazobactam and cefepime for the empirical treatment of febrile neutropenic episodes in patients with hematologic malignancies. Clin Infect Dis 2006;43(4):447-59.
39. Cherif H, Bjorkholm M, Engervall P, et al. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Scand J Infect Dis 2004;36(8):593-600.
40. Harter C, Schulze B, Goldschmidt H, et al. Piperacillin/tazobactam vs ceftazidime in the treatment of neutropenic fever in patients with acute leukemia or following autologous peripheral blood stem cell transplantation: A prospective randomized trial. Bone Marrow Transplant 2006;37(4):373-9.
41. Jaksic B, Martinelli G, Perez-Oteyza J, Hartman CS, Leonard LB, Tack KJ. Efficacy and safety of linezolid compared with vancomycin in a randomized, double-blind study of febrile neutropenic patients with cancer. Clin Infect Dis 2006;5:597-607.
42. Oztoprak N, Piskin N, Aydemir H, et al. Piperacillin-tazobactam versus carbapenem therapy with and without amikacin as empirical treatment of febrile neutropenia in cancer patients: Results of an open randomized trial at a university hospital. Jpn J Clin Oncol 2010;40(8):761-7.
43. Raad II, Escalante C, Hachem RY, et al. Treatment of febrile neutropenic patients with cancer who require hospitalization: A prospective randomized study comparing imipenem and cefepime. Cancer 2003;98(5):1039-47.
44. Sanz MA, Lopez J, Lahuerta JJ, et al. Cefepime plus amikacin versus piperacillin-tazobactam plus amikacin for initial antibiotic therapy in haematology patients with febrile neutropenia: Results of an open, randomized, multicentre trial. J Antimicrob Chemother 2002;50(1):79-88.
45. Arango JI, Restrepo A, Schneider DL, et al. Incidence of Clostridium difficile-associated diarrhea before and after autologous peripheral blood stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant 2006;37 (5):517-21.
46. Dubberke ER, Reske KA, Srivastava A, et al. Clostridium difficile- associated disease in allogeneic hematopoietic stem-cell transplant recipients: Risk associations, protective associations, and outcomes. Clin Transplant 2010;24(2):192-8.
47. Gifford AH, Kirkland KB. Risk factors for Clostridium difficile-associated diarrhea on an adult hematology-oncology ward. Eur J Clin Microbiol Infect Dis 2006;25(12): 751-5.
48. Palmore TN, Sohn S, Malak SF, Eagan J, Sepkowitz KA. Risk factors for acquisition of Clostridium difficile-associated diarrhea among outpatients at a cancer hospital. Infect Control Hosp Epidemiol 2005;26(8):680-4.
49. Schalk E, Bohr UR, Konig B, Scheinpflug K, Mohren M. Clostridium difficile-associated diarrhoea, a frequent complication in patients with acute myeloid leukaemia. Ann Hematol 2009;89(1):9-14.
50. Forrest GN. Controversies in antimicrobial stewardship. In: Safdar A, ed. Principles and practice of cancer infectious diseases. New York: Humana Press, 2011:499-506.
51. Hendricks AM, Loggers ET, Talcott JA. Costs of home versus inpatient treatment for fever and neutropenia: Analysis of a multicenter randomized trial. J Clin Oncol 2011;29(30): 3984-9.
52. Rolston KV, Manzullo EF, Elting LS, et al. Once daily, oral, outpatient quinolone monotherapy for low-risk cancer patients with fever and neutropenia: A pilot study of 40 patients based on validated risk-prediction rules. Cancer 2006;106(11):2489-94.
53. Talcott JA, Yeap BY, Clark JA, et al. Safety of early discharge for low-risk patients with febrile neutropenia: A multicenter randomized controlled trial. J Clin Oncol 2011;29(30):3977-83.
54. Coleman RW, Rodondi LC, Kaubisch S, Granzella NB, O'Hanley PD. Cost-effectiveness of prospective and continuous parenteral antibiotic control: Experience at the Palo Alto Veterans Affairs Medical Center from 1987 to 1989. Am J Med 1991;90(4):439-44.
55. White AC Jr, Atmar RL, Wilson J, Cate TR, Stager CE, Greenberg SB. Effects of requiring prior authorization for selected antimicrobials: Expenditures, susceptibilities, and clinical outcomes. Clin Infect Dis 1997;25(2):230-9.
56. Ananda-Rajah MR, Cheng A, Morrissey CO, et al. Attributable hospital cost and antifungal treatment of invasive fungal diseases in high-risk hematology patients: An economic modeling approach. Antimicrob Agents Chemother 2011;55(5):1953 -60.
57. Slavin MA, Sorrell TC, Marriott D, et al. Candidaemia in adult cancer patients: Risks for fluconazole-resistant isolates and death. J Antimicrob Chemother 2010;65(5):1042-51.
58. Trifilio SM, Bennett CL, Yarnold PR, et al. Breakthrough zygomycosis after voriconazole administration among patients with hematologic malignancies who receive hematopoietic stem-cell transplants or intensive chemotherapy. Bone Marrow Transplant 2007;39(7):425-9.
59. Hussaini T, Ruping MJ, Farowski F, Vehreschild JJ, Cornely OA. Therapeutic drug monitoring of voriconazole and posaconazole. Pharmacotherapy 2011;31(2):214-25.
60. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008;46(2):201-11.
61. Ananda-Rajah MR, Slavin MA, Thursky KT. The case for antifungal stewardship. Curr Opin Infect Dis 2012;25(1):107-15.
62. Sakr Y, Sponholz C, Tuche F, Brunkhorst F, Reinhart K. The role of procalcitonin in febrile neutropenic patients: Review of the literature. Infection 2008;36(5):396-407.
63. Liew YX, Chlebicki MP, Lee W, Hsu LY, Kwa AL. Use of procalcitonin (PCT) to guide discontinuation of antibiotic use in an unspecified sepsis is an antimicrobial stewardship program (ASP). Eur J Clin Microbiol Infect Dis 2011;30(7):853-5.
64. Hayashi Y, Paterson DL. Strategies for reduction in duration of antibiotic use in hospitalized patients. Clin Infect Dis 2011;52(10):1232-40.
65. Agwu AL, Lee CK, Jain SK, et al. A World Wide Web-based antimicrobial stewardship program improves efficiency, communication, and user satisfaction and reduces cost in a tertiary care pediatric medical center. Clin Infect Dis 2008;6:747-53.
66. Charani E, Edwards R, Sevdalis N, et al. Behavior change strategies to influence antimicrobial prescribing in acute care: A systematic review. Clin Infect Dis 2011;53(7):651-62.